Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Mark Mittauer

Psychiatry Groton, CT Medical Doctor

NPI 1255322996 CMS profile 238532

Rte 12 Bldg 449, Groton, CT 06349

Open in the dashboard

General payments

$22,988

622 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mark Mittauer of Groton, CT is reported in the CMS Open Payments database as having received $22,988 across 622 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,018 130
2024 General $1,058 66
2023 General $901 48
2022 General $2,802 92
2021 General $9,101 106
2020 General $2,266 46
2019 General $4,842 134

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mark Mittauer
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Mark Mittauer were reported at $2,018. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Mark Mittauer Psychiatry median Middle half National median
2019 $4,842 $184 $59–$605 $163
2020 $2,266 $119 $36–$372 $114
2021 $9,101 $143 $43–$576 $132
2022 $2,802 $153 $50–$590 $149
2023 $901 $170 $56–$651 $160
2024 $1,058 $179 $57–$673 $164
2025 $2,018 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $8,773 86 payments
  2. Allergan Inc. $4,868 18 payments
  3. Otsuka America Pharmaceutical, Inc. $3,044 70 payments
  4. Janssen Pharmaceuticals, Inc $901 72 payments
  5. Neurocrine Biosciences, Inc. $885 91 payments
  6. ITI, Inc. $800 56 payments
  7. Alkermes, Inc. $697 44 payments
  8. Teva Pharmaceuticals USA, Inc. $669 36 payments
  9. Lundbeck LLC $469 44 payments
  10. Sunovion Pharmaceuticals Inc. $356 28 payments
  11. Other $1,525 77 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $13,462 12 payments
  2. Food and Beverage $8,280 602 payments
  3. Travel and Lodging $1,110 4 payments
  4. Education $136 4 payments
Products named General payments · program years 2019–2025
  1. VRAYLAR Neuroscience $9,996 63 payments
  2. VRAYLAR Neuroscience $3,646 41 payments
  3. REXULTI $2,791 54 payments
  4. CAPLYTA $695 51 payments
  5. ARISTADA Cns $666 42 payments
  6. ARISTADA Cns $666 42 payments
  7. ARISTADA Cns $652 41 payments
  8. ARISTADA Cns $652 41 payments
  9. INGREZZA $640 77 payments
  10. SPRAVATO $596 40 payments
  11. Other $5,373 377 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

137

Median for Psychiatry: 574

Drug cost

$1,492

Median for Psychiatry: $27,624

Branded share of claims

28.5%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Divalproex Sodium Er Divalproex Sodium Brand 12 $254
Bupropion Xl Bupropion Hcl Brand 14 $243
Escitalopram Oxalate Generic 16 $240
Duloxetine Hcl Generic 22 $232
Lamotrigine Generic 17 $191
Trazodone Hcl Generic 16 $95
Alprazolam Generic 14 $83
Clonidine Hcl Generic 13 $76
Citalopram Hbr Citalopram Hydrobromide Brand 13 $75

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 15 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
SPRAVATO
  • Janssen Pharmaceuticals, Inc $183
$183 — —
ARISTADA
  • Alkermes, Inc. $150
$150 — —
INGREZZA
  • Neurocrine Biosciences, Inc. $149
$149 — —
CAPLYTA
  • ITI, Inc. $146
$146 — —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $53
  • Lundbeck LLC $34
$87 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 15 in the dashboard with a free account

Records

622 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Connecticut

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record